{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:04:25Z","timestamp":1777302265629,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82001338"],"award-info":[{"award-number":["82001338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2020JJ4854"],"award-info":[{"award-number":["2020JJ4854"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2021JJ40934"],"award-info":[{"award-number":["2021JJ40934"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2020JJ5867"],"award-info":[{"award-number":["2020JJ5867"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changsha Natural Science Foundation","award":["kq2208351"],"award-info":[{"award-number":["kq2208351"]}]},{"name":"Special Funding for the Construction of Innovative Provinces in Hunan","award":["2020SK2055"],"award-info":[{"award-number":["2020SK2055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new diagnostic criterion based on hepatic steatosis and metabolic dysfunction. However, a comprehensive evaluation of the association of MAFLD dynamic transitions with arterial stiffness progression has yet to be conducted. This cohort study included 8807 Chinese health check-up participants (median follow-up\u2009=\u200950.2\u00a0months). Participants were categorized into four groups according to MAFLD status at baseline and follow-up (none, persistent, developed and regressed). Arterial stiffness progression was assessed by the annual brachial-ankle pulse wave velocity (ba-PWV) increase and arterial stiffness incidence. Compared with the non-MAFLD group, the annual increase in ba-PWV was highest in the persistent-MAFLD group [6.75\u00a0cm\/s\/year, (95% CI 4.03\u20139.33)], followed by the developed\u2014[6.35\u00a0cm\/s\/year, (95% CI 3.80\u20138.91)] and the regressed\u2014[1.27\u00a0cm\/s\/year, (95% CI \u2212\u00a02.18 to 4.72)] MAFLD groups. Similarly, compared with the non-MAFLD group, the persistent-MAFLD group had a 1.31-fold increased arterial stiffness risk [OR 1.31; 95% CI 1.03\u20131.66]. The associations of MAFLD transition patterns with arterial stiffness incidence did not differ across any clinically specific subgroups evaluated. Furthermore, the potential effect of dynamic changes in cardiometabolic risk factors on arterial stiffness incidence among persistent-MAFLD participants was mostly driven by annual fasting glucose and triglyceride increases. In conclusion, persistent MAFLD was associated with an increased risk of arterial stiffness development. Moreover, in persistent-MAFLD subjects, elevated blood glucose and triglyceride levels might facilitate the arterial stiffness incidence.<\/jats:p>","DOI":"10.1038\/s41598-023-35733-0","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:02:34Z","timestamp":1686819754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Lei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changfa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"1","key":"35733_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1), 328\u2013357 (2018).","journal-title":"Hepatology"},{"issue":"1","key":"35733_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73\u201384 (2016).","journal-title":"Hepatology"},{"issue":"5","key":"35733_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li, J. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 4(5), 389\u2013398 (2019).","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"35733_CR4","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J Hepatol 62(1 Suppl), S47\u2013S64 (2015).","journal-title":"J Hepatol"},{"issue":"7","key":"35733_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam, M., Sanyal, A. J. & George, J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 158(7), 1999\u20132014 (2020).","journal-title":"Gastroenterology"},{"issue":"6","key":"35733_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","volume":"40","author":"Y Fouad","year":"2020","unstructured":"Fouad, Y. et al. What\u2019s in a name?. Renaming \u201cNAFLD\u201d to \u201cMAFLD\u201d. Liver Int 40(6), 1254\u20131261 (2020).","journal-title":"Renaming 'NAFLD' to 'MAFLD'. Liver Int"},{"issue":"1","key":"35733_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 73(1), 202\u2013209 (2020).","journal-title":"J Hepatol"},{"issue":"5","key":"35733_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cgh.2021.01.017","volume":"19","author":"WV Wai-Sun","year":"2021","unstructured":"Wai-Sun, W. V. & Kanwal, F. On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol 19(5), 865\u2013870 (2021).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"35733_CR9","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","volume":"20","author":"RJ Wong","year":"2022","unstructured":"Wong, R. J. & Cheung, R. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011\u20132018. Clin Gastroenterol Hepatol 20(3), e610\u2013e613 (2022).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"35733_CR10","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. J Clin Endocrinol Metab 107(2), e745\u2013e755 (2022).","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"35733_CR11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee, H. et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 19(10), 2138\u20132147 (2021).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"35733_CR12","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000435","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee, H. et al. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. Clin Transl Gastroenterol 13(1), e435 (2022).","journal-title":"Clin Transl Gastroenterol"},{"issue":"11","key":"35733_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi, T. et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 51(11), 1115\u20131128 (2021).","journal-title":"Hepatol Res"},{"issue":"10","key":"35733_CR14","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Dig Dis Sci 67(10), 4919\u20134928 (2022).","journal-title":"Dig Dis Sci"},{"issue":"4","key":"35733_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"YY Zhou","year":"2018","unstructured":"Zhou, Y. Y. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun 2(4), 376\u2013392 (2018).","journal-title":"Hepatol Commun"},{"issue":"5","key":"35733_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","volume":"68","author":"SB Lee","year":"2018","unstructured":"Lee, S. B. et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol 68(5), 1018\u20131024 (2018).","journal-title":"J Hepatol"},{"issue":"3","key":"35733_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","volume":"151","author":"DH Sinn","year":"2016","unstructured":"Sinn, D. H. et al. Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology 151(3), 481\u2013488 (2016).","journal-title":"Gastroenterology"},{"key":"35733_CR18","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","volume":"16","author":"H Lee","year":"2022","unstructured":"Lee, H. et al. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol. Int. 16, 1308\u20131313 (2022).","journal-title":"Hepatol. Int."},{"issue":"1","key":"35733_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-022-01518-4","volume":"21","author":"Y Matsubayashi","year":"2022","unstructured":"Matsubayashi, Y. et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc. Diabetol. 21(1), 90 (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"35733_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269265","volume":"17","author":"R Bessho","year":"2022","unstructured":"Bessho, R. et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE 17(5), e269265 (2022).","journal-title":"PLoS ONE"},{"issue":"11","key":"35733_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda, M. et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan. J. Gastroenterol. 56(11), 1022\u20131032 (2021).","journal-title":"J. Gastroenterol."},{"issue":"4","key":"35733_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5009\/gnl210256","volume":"16","author":"S Jeong","year":"2022","unstructured":"Jeong, S. et al. Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. Gut Liver 16(4), 589\u2013598 (2022).","journal-title":"Gut Liver"},{"issue":"8","key":"35733_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jacc.2019.12.039","volume":"75","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Trajectories of age-related arterial stiffness in Chinese Men and Women. J. Am. Coll. Cardiol. 75(8), 870\u2013880 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"35733_CR24","doi-asserted-by":"publisher","first-page":"14786","DOI":"10.1038\/s41598-022-18988-x","volume":"12","author":"L Lei","year":"2022","unstructured":"Lei, L. et al. Association between non-alcoholic fatty liver disease and metabolically healthy deterioration across different body shape phenotypes at baseline and change patterns. Sci. Rep. 12(1), 14786 (2022).","journal-title":"Sci. Rep."},{"issue":"4","key":"35733_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou, F. et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology 70(4), 1119\u20131133 (2019).","journal-title":"Hepatology"},{"issue":"9","key":"35733_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.12647","volume":"46","author":"W Sun","year":"2016","unstructured":"Sun, W. et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol. Res. 46(9), 862\u2013870 (2016).","journal-title":"Hepatol. Res."},{"issue":"1","key":"35733_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.ackd.2017.10.005","volume":"25","author":"BW Teo","year":"2018","unstructured":"Teo, B. W. et al. Glomerular filtration rates in Asians. Adv. Chronic Kidney Dis. 25(1), 41\u201348 (2018).","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"8","key":"35733_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1291\/hypres.26.615","volume":"26","author":"A Yamashina","year":"2003","unstructured":"Yamashina, A. et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens. Res. 26(8), 615\u2013622 (2003).","journal-title":"Hypertens. Res."},{"issue":"3","key":"35733_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher, G. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J. Hepatol. 65(3), 589\u2013600 (2016).","journal-title":"J. Hepatol."},{"issue":"11","key":"35733_CR30","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00125-008-1135-4","volume":"51","author":"G Targher","year":"2008","unstructured":"Targher, G., Marra, F. & Marchesini, G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon?. Diabetologia 51(11), 1947\u20131953 (2008).","journal-title":"Diabetologia"},{"issue":"1","key":"35733_CR31","first-page":"10","volume":"107","author":"J Ampuero","year":"2015","unstructured":"Ampuero, J., Gallego-Dur\u00e1n, R. & Romero-G\u00f3mez, M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: Meta-analysis. Rev. Esp. Enferm. Dig. 107(1), 10\u201316 (2015).","journal-title":"Rev. Esp. Enferm. Dig."},{"issue":"8","key":"35733_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep4.1199","volume":"2","author":"D Kapuria","year":"2018","unstructured":"Kapuria, D. et al. Association of hepatic steatosis with subclinical atherosclerosis: Systematic review and meta-analysis. Hepatol. Commun. 2(8), 873\u2013883 (2018).","journal-title":"Hepatol. Commun."},{"key":"35733_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154779","volume":"120","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. Metabolism 120, 154779 (2021).","journal-title":"Metabolism"},{"key":"35733_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110108","volume":"192","author":"L Lei","year":"2022","unstructured":"Lei, L. et al. Metabolically healthy transition and its association with body size change patterns among different adult age groups. Diabetes Res. Clin. Pract. 192, 110108 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"35733_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2011.08.041","volume":"220","author":"V Bieghs","year":"2012","unstructured":"Bieghs, V. et al. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 220(2), 287\u2013293 (2012).","journal-title":"Atherosclerosis"},{"issue":"5","key":"35733_CR36","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/nu5051544","volume":"5","author":"M Gaggini","year":"2013","unstructured":"Gaggini, M. et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5(5), 1544\u20131560 (2013).","journal-title":"Nutrients"},{"issue":"7","key":"35733_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg, H. & Effenberger, M. From NAFLD to MAFLD: When pathophysiology succeeds. Nat. Rev. Gastroenterol. Hepatol. 17(7), 387\u2013388 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"35733_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/ijms17040460","volume":"17","author":"CA Villela-Nogueira","year":"2016","unstructured":"Villela-Nogueira, C. A. et al. NAFLD and increased aortic stiffness: Parallel or common physiopathological mechanisms?. Int. J. Mol. Sci. 17(4), 460 (2016).","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"35733_CR39","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","volume":"7","author":"L Polimeni","year":"2015","unstructured":"Polimeni, L. et al. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J. Hepatol. 7(10), 1325\u20131336 (2015).","journal-title":"World J. Hepatol."},{"issue":"16","key":"35733_CR40","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3748\/wjg.v26.i16.1861","volume":"26","author":"J Alharthi","year":"2020","unstructured":"Alharthi, J. et al. Macrophages in metabolic associated fatty liver disease. World J. Gastroenterol. 26(16), 1861\u20131878 (2020).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"35733_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.20781","volume":"42","author":"N Villanova","year":"2005","unstructured":"Villanova, N. et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42(2), 473\u2013480 (2005).","journal-title":"Hepatology"},{"issue":"2","key":"35733_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2014.09.011","volume":"237","author":"S Jain","year":"2014","unstructured":"Jain, S. et al. Inflammation and arterial stiffness in humans. Atherosclerosis 237(2), 381\u2013390 (2014).","journal-title":"Atherosclerosis"},{"issue":"37","key":"35733_CR43","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.3748\/wjg.v20.i37.13306","volume":"20","author":"S Fargion","year":"2014","unstructured":"Fargion, S., Porzio, M. & Fracanzani, A. L. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J. Gastroenterol. 20(37), 13306\u201313324 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"35733_CR44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam, M. et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol. Hepatol. 6(9), 743\u2013753 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"35733_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.14309\/ajg.0000000000000572","volume":"115","author":"E Han","year":"2020","unstructured":"Han, E. et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am. J. Gastroenterol. 115(4), 584\u2013595 (2020).","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"35733_CR46","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1111\/jgh.15589","volume":"36","author":"N Tamaki","year":"2021","unstructured":"Tamaki, N. et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J. Gastroenterol. Hepatol. 36(10), 2960\u20132966 (2021).","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35733-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T10:10:01Z","timestamp":1686823801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35733-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35733"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35733-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9690"}}